|
|
|
 |
Search published articles |
 |
|
Showing 3 results for Hekmatdoost
Azita Hekmatdoost,
Volume 5, Issue 2 (Apr-Jun 2018)
Abstract
| nflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), has become one of the most common chronic conditions all over the world. The prevalence of IBD is growing rapidlyin developing countries along with nutrition transition. IBD affects children as well as adults, with 15-20% of patients being diagnosed during childhood. The onset of disease during childhood is important because it affects child growth and development (1, 2). Moreover, when IBD initiates during childhood, it is usually more severe and involves more regions of the gut. Weight loss, failure to thrive, low bone density, and late puberty are the typical problems in pediatric CD due to malnutrition which subsequently results in malabsorption. Treatment by corticosteroids aggravates growth problems and worsens malnutrition in the affected children. Currently, exclusive enteral nutrition (EEN) is recommended as the first line of treatment in pediatric CD (3). Meta-analysis of clinical trials has shown that EEN is as effective as corticosteroids in giving rise to remission in children suffering from CD, with 80% success of active CD treatment (4). If patient does not respond to EEN after 2 weeks, other therapeutic options should be considered. If two weeks administration of EEN induces remission, EEN should be continued for 6-8 weeks. Then, solid foods can be introduced gradually to the patients' diet during a period of 2-3 weeks. The first group of solid foods, which can be consumed, are low fiber grains such as white flour bread, crackers, pasta, and rice. After 3-4 days, low fat meats and alternatives such as plain (not fried, not processed) lamb, veal, beef, chicken, turkey, fish (low fat), tofu, and eggs can be used. From the tenth day, low fiber fruits and vegetables such as fruits without skin/seeds, cooked vegetables without skin/seeds can be eaten. Finally, low fat dairy products are added to the diet on the fifteenth day, and gradually patients can use a regular diet as tolerated. For maintenance, patients can use EEN in one out of every 4 months in the year or be fed nocturnal partial enteral nutrition (PEN) for 4-5 days every week (3, 5). |
Current evidence has shown that neither type of the formula nor the location of gut injury is a determinant of the effectiveness of EEN for CD treatment in children. If patient prefers to drink formula, then polymeric formulas are good choices for feeding. When the child cannot drink the whole volume of dietary needs, the patient can be fed by naso-gastric (NG) tube (6).
The mechanism of action in EEN treatment of CD has not yet been fully elucidated, however, the probable mechanisms includes low allergen load, absence of food additives, being nucleotide free, and an anti-inflammatory lipid composition. Recently, it has been hypothesized that EEN has a specific effect on the intestinal microbiome, positively interfering with the dysbiosis in CD patients (3, 5, 7). Further studies are needed to evaluate the exact mechanism of action of this treatment. Moreover, producing high quality formulas with good taste and low price are absolutely needed in low income countries because the cost of long EEN is not affordable for many patients in these countries.
Azita Hekmatdoost, Vahideh Behrouz, Zahra Yari,
Volume 11, Issue 3 (Jul-Sep 2024)
Abstract
Background and Objectives: Regarding the increasing prevalence of metabolic syndrome (MetS), and its association with non-communicable chronic diseases, providing preventive and therapeutic strategies is a priority. A randomized controlled study was conducted to assess the effects of combination therapy of milled brown flaxseed and hesperidin during lifestyle intervention on MetS components.
Materials and Methods: Forty-eight subjects were randomly assigned to receive lifestyle intervention plus combination therapy of brown flaxseed (30 g milled) and hesperidin (two 500 mg capsules) or lifestyle modification alone for 12 weeks. MetS was assessed as a primary endpoint. The trial was registered in clinicaltrial.gov:NCT03737422.
Results: Forty-six percent of patients in the flaxseed-hesperidin group experienced more than three MetS factors improvement from baseline to week 12, while only 17% of patients in the control group fall in this category. A comparison of blood pressure changes throughout the study indicated a greater reduction in blood pressure in the intervention group rather than in the control group (-5.66 vs. -1.56 mmHg, P = 0.049). The reduction in plasma glucose (-20.35 vs. -7.46 mg/dL, P = 0.007) and triglyceride (-45.3 vs. -8.39 mg/dL, P = 0.020) in the flaxseed-hesperidin group was significantly more than the control group after 12 weeks of intervention.
Conclusions: Our results indicate that co-administration of flaxseed and hesperidin as an adjunct to lifestyle modification program is more effective than lifestyle modification alone in the treatment of metabolic syndrome.
Samira Rabiei, Azita Hekmatdoost, Vahideh Behrouz, Zahra Yari,
Volume 11, Issue 4 (Oct-Dec 2024)
Abstract
Background and Objectives: The increase in the risk of cardiovascular diseases, one of the leading causes of death in the world, due to obesity is significant. This study was carried out suggesting palliative effects of the combination of brown flaxseed and hesperidin on atherogenic dyslipidemia in obese people.
Materials and Methods: In this randomized controlled study, 44 obese adults were randomly assigned to lifestyle modification (control group) or receiving combined brown flaxseed (30 g) and hesperidin (2 × 500 mg capsules) (intervention group) for 12 w. Atherogenic indices, anthropometric parameters and dietary intakes were recorded. The trial was registered in clinicaltrial.gov. with reg. no. NCT03737422.
Results: After 12 w of intervention, body mass index decreased significantly in groups; however, decrease of body mass index in intervention group was significantly higher than that in control group (p = 0.034). Comparing changes of atherogenic indices between the two groups indicated a significant difference in triglyceride glucose index, atherogenic index of plasma and cholesterol index between the two groups. After adjusting results for condetecteders, including baseline value of the outcome and mean changes in body mass index, waist circumference and energy intake, differences became significant for Castelli risk index-II and lipoprotein combine index.
Conclusions: The current results have shown that intake of a combination of flaxseed and hesperidin with lifestyle modification effectively improves atherogenic dyslipidemia.
|
|
